Interactions between antifungal and antiretroviral agents

Bibliography

• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 1 December 2009; 1-161. Available from: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf [Accessed 7 December 2009]
   Google Scholar
• Centers for Disease Control and Prevention. Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. MMWR 2009;58(RR-4):1-207
   PubMedGoogle Scholar
• Ruhnke M. Mucosal and systemic fungal infections in patients with AIDS. Drugs 2004;64:1163-80
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992;41(RR-17):1-19
   Google Scholar
• Tran JQ, Petersen C, Garrett M, Delavirdine significantly increases plasma concentrations of amprenavir in healthy volunteers. AIDS 2000;14 (Suppl 4):S92
   PubMedGoogle Scholar
• Pfizer Canada, Inc. Rescriptor (delavirdine) Product Monograph. Kirkland, QC; 4 September 2004
   Google Scholar
• Bristol-Myers Squibb Canada. Sustiva (efavirenz) Product Monograph. Montreal, QC; rev 2 July 2009
   Google Scholar
• Janssen-Ortho, Inc. Intelence (etravirine) Product Monograph. Toronto, ON; rev 28 October 2008
   Google Scholar
• Scholler-Gyure M, Kakuda TN, Stevens T, Effect of etravirine on cytochrome P450 isozymes assessed by the Cooperstown 5+1 cocktail [abstract A-955]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC; 25 – 28 October 2008
   Google Scholar
• Robertson SM, Maldarelli F, Natarajan V, Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects. J Acquir Immune Defic Syndr 2008;49:513-9
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim (Canada) Ltd. Viramune (nevirapine) Product Monograph. Burlington, ON; rev 7 July 2009
   Google Scholar
• Soodalter J, Sousa M, Boffito M. Drug-drug interactions involving new antiretroviral drugs and drug classes. Curr Opin Infect Dis 2009;22:18-27
   PubMed Web of Science ®Google Scholar
• Hariparsad N, Sane R, Desai PB. Induction of PXR target genes by non-nucleoside reverse transcriptase inhibitor, efavirenz, and protease inhibitors [PIs] ritonavir and nelfinavir. Presented at: American Association of Pharmaceutical Scientists Annual Meeting, Nashville, TN; 6 – 10 November 2005
   Google Scholar
• Mossdorf E, Kummer O, Kraehenbueh S, Efavirenz induction of the UGT-1A1 reduces atazanavir induced hyperbilirubinemia. Presented at: 8th International Congress on Drug Therapy in HIV Infection; Glasgow, United Kingdom; 12 – 16 November 2006
   Google Scholar
• Bristol-Myers Squibb Canada. Reyataz (atazanavir) Product Monograph. Montreal, QC; 22 April 2008
   Google Scholar
• Janssen-Ortho, Inc. Prezista (darunavir) Product Monograph. Toronto, Ontario; 12 March 2009
   Google Scholar
• GlaxoSmithKline. Telzir (fosamprenavir) Product Monograph. Mississauga, ON; 27 May 2009
   Google Scholar
• Merck Frosst Canada Ltd. Crixivan (indinavir) Product Monograph. Kirkland, QC; 27 March 2009
   Google Scholar
• Abbott Laboratories Limited Canada. Kaletra (lopinavir/ritonavir) Product Monograph. Saint Laurent, QC; 10 June 2008
   Google Scholar
• Pfizer Canada, Inc. Viracept (nelfinavir) Product Monograph. Kirkland, QC; 29 May 2008
   Google Scholar
• Abbott Laboratories Limited Canada. Norvir (ritonavir) Product Monograph. Saint-Laurent, QC; 5 June 2008
   Google Scholar
• Hoffmann-La Roche Ltd. Invirase (saquinavir) Product Monograph. Mississauga, ON; 12 August 2008
   Google Scholar
• Boehringer Ingelheim. Aptivus (tipranavir) Product Monograph. Burlington, ON; 8 May 2008
   Google Scholar
• Vourvahis M, Dumond J, Patterson K, Effects of tipranavir/ritonavir on the activity of cytochrome p450 enzymes 1A2, 2C9 and 2D6 in healthy volunteers [abstract 52]. 8th International Workshop on Clinical Pharmacology of HIV Therapy, Budapest, Hungary; 16 – 18 April 2007
   Google Scholar
• Dixit V, Hariparsad N, Li F, Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. Drug Metab Dispos 2007;35:1853-9
   PubMed Web of Science ®Google Scholar
• Kharasch ED, Mitchell D, Coles R, Blanco R. Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. Antimicrob Agents Chemother 2008;52:1663-9
   PubMed Web of Science ®Google Scholar
• Pfizer Canada, Inc. Celsentri (maraviroc) Product Monograph. Kirkland, QC; 11 February 2009
   Google Scholar
• Merck Frosst Canada Ltd. Isentress (raltegravir) Product Monograph. Kirkland, QC; 2 April 2009
   Google Scholar
• e-CPS [Internet]. Ottawa (ON): Canadian Pharmacists Association; c2009. Fungizone [product monograph]. Available from: http://www.e-cps.ca. [Revised 1 June 2009; cited 7 December 2009]
   Google Scholar
• Moen MD, Lysend-Williamson KA, Scott LJ. Liposomal Amphotericin B. A review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Drugs 2009;69:361-92
   PubMed Web of Science ®Google Scholar
• Guest J, Rimland D, Patterson B, Desilva K. Tenofovir-induced nephrotoxicity in the first year of therapy [abstract 778]. 13th Conference on retroviruses and opportunistic infections, Denver, Colorado; 5 – 8 February 2006
   Google Scholar
• GlaxoSmithKline, Inc. Retrovir (zidovudine) Product Monograph. Mississauga, ON; 12 March 2009
   Google Scholar
• Koltin Y, Hitchcock CA. The search for new triazole antifungal agents. Curr Opin Chem Biol 1997;1:176-82
   PubMed Web of Science ®Google Scholar
• Nivoix Y, Leveque D, Herbrecht R, The enzymatic basis of drug-drug interactions with systemic triazole antifungals. Clin Pharmacokinet 2008;47:779-92
   PubMed Web of Science ®Google Scholar
• Janssen-Ortho, Inc. Sporanox (itraconazole) Product Monograph. Toronto, ON; 20 May 2008
   Google Scholar
• Humphrey MJ, Jevons S, Tarbit MH. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob Agents Chemother 1985;28:648-53
   PubMed Web of Science ®Google Scholar
• Bruggemann RJM, Alffenaar J-WC, Blijlevens NMA, Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other co-administered agents. Clin Infect Dis 2009;48:1441-58
   PubMed Web of Science ®Google Scholar
• Black DJ, Kunze KL, Wienkers LC, Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies. Drug Metab Dispos 1996;24:422-8
   PubMed Web of Science ®Google Scholar
• Wang EJ, Lew K, Casciano CN, Interaction of common azole antifungals with P glycoprotein. Antimicrob Agents Chemother 2002;46:160-5
   PubMed Web of Science ®Google Scholar
• Takano M, Hasegawa R, Fukuda T, Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells. Eur J Pharmacol 1998;358:289-94
   PubMed Web of Science ®Google Scholar
• Asgari M, Back DJ. Effect of azoles on the glucuronidation of zidovudine by human liver UDP-glucuronosyltransferase [letter; comment]. J Infect Dis 1995;172:1634-6
   PubMed Web of Science ®Google Scholar
• Sampol E, Lacarelle B, Rajaonarison JF, Comparative effects of antifungal agents on zidovudine glucuronidation by human liver microsomes. Br J Clin Pharmacol 1995;40:83-6
   PubMed Web of Science ®Google Scholar
• Blum RA, D'Andrea DT, Florentino BM, Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med 1991;114:755-7
   PubMed Web of Science ®Google Scholar
• Daneshmend TK, Warnock DW. Clinical pharmacokinetics of ketoconazole. Clin Pharmacokinet 1988;14:13-34
   PubMed Web of Science ®Google Scholar
• Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994;330:263-72
   PubMed Web of Science ®Google Scholar
• Back DJ, Tjia JF. Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Br J Clin Pharmacol 1991;32:624-6
   PubMed Web of Science ®Google Scholar
• Takano M, Hasegawa R, Fukuda T, Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells. Eur J Pharmacol 1998;358:289-94
   PubMed Web of Science ®Google Scholar
• Lamson M, Robinson P, Gigliotti M, Myers M. The pharmacokinetic interactions of nevirapine and ketoconazole [abstract 12218]. 12th World AIDS Conference, Geneva, Switzerland; June 28 – July 3 1998
   Google Scholar
• Sriwiriyajan S, Mahatthanatrakul W, Ridtitid W, Jaruratanasirikul S. Effect of efavirenz on the pharmacokinetics of ketoconazole in HIV-infected patients. Eur J Clin Pharmacol 2007;63:479-83
   PubMed Web of Science ®Google Scholar
• Van Heeswijk RP, Hoetelmans RM, Kestens D, The pharmacokinetic interaction between ketoconazole and TMC278, an investigational non-nucleoside reverse transcriptase inhibitor in healthy, HIV-negative subjects [abstract TUPE0087]. XVI International AIDS Conference, Toronto, Canada; 13 – 18 August 2006
   Google Scholar
• Kaeser B, Zandt H, Bour F, Drug-drug interaction study of ketoconazole and ritonavir-boosted saquinavir. Antimicrob Agents Chemother 2009;53:609-14
   PubMed Web of Science ®Google Scholar
• Sekar V, Lefebvre E, De Pauw M, Pharmacokinetics of darunavir/ritonavir and ketoconazole following co-administration in HIV-healthy volunteers. Br J Clin Pharmacol 2008;66:215-21
   PubMed Web of Science ®Google Scholar
• O'Mara E, Randall D, Uderman H, Steady-state pharmacokinetic interaction study between BMS-232632 and ketoconazole in healthy subjects [abstract 1646]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada; 17 – 20 September 2000
   Google Scholar
• Polk RE, Crouch M, Israel DS, Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men. Pharmacotherapy 1999;19:1378-84
   PubMed Web of Science ®Google Scholar
• Kerr B, Lee C, Yuen G, Overview of in-vitro and in-vivo drug interaction studies of nelfinavir mesylate, a new HIV-1 protease inhibitor [abstract 373]. 4th Conference on Retroviruses and Opportunistic Infections, Washington DC; 22 – 26 January 1997
   Google Scholar
• Abel S, Russell D, Ridgway C, Muirhead G. Overview of the drug-drug interaction data for maraviroc (UK-427,857) [abstract 76]. 6th International Workshop on Clinical Pharmacology of HIV Therapy Quebec; 28 – 30 April 2005
   Google Scholar
• Pfizer Canada, Inc. Diflucan (fluconazole) Product Monograph. Kirkland, QC; 3 March 2004
   Google Scholar
• Scholler-Gyure M, Kakuda TN, Van Solingen-Ristea R, Pharmacokinetic interaction between etravirine and fluconazole or voriconazole in HIV-negative volunteers [abstract A1-1299]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco; 12 – 15 September 2009
   Google Scholar
• Geel J, Pitt J, Orrell C, The effect of fluconazole on nevirapine pharmacokinetics [abstract WeOrB1239]. XV International AIDS Conference, Bangkok, Thailand; 11 – 16 July 2004
   Google Scholar
• Manosuthi W, Athichathanabadi C, Uttayamakul S, Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole. BMC Infect Dis 2007;7:14-21
   PubMedGoogle Scholar
• Wakeham K, Parkes R, Watson V, Co-administration of fluconazole increases nevirapine concentrations in HIV infected Ugandans [abstract 700]. 16th Conference on Retroviruses and Opportunistic Infections, Montreal, QC; 8 – 11 February 2009
   Google Scholar
• Kerr B, Yuen G, Daniels R, Strategic approach to nelfinavir mesylate (NFV) drug interactions involving CYP3A metabolism. 4th National Conference on Retroviruses and Opportunistic Infections, Washington DC; 1997
   Google Scholar
• Agarwala S, Gray K, Nettles R, Lack of pharmacokinetic interaction between atazanavir, ritonavir and fluconazole dosed to steady-state in healthy subjects [abstract A-0382]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco, CA; 27 – 30 September 2006
   Google Scholar
• La Porte CJL, Sabo JP, Elgadi M, Cameron DW. Interaction studies of tipranavir-ritonavir with clarithromycin, fluconazole, and rifabutin in healthy volunteers. Antimicrob Agents Chemother 2009;53:162-73
   PubMed Web of Science ®Google Scholar
• Sahai J, Gallicano K, Pakuts A, Cameron DW. Effect of fluconazole on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus [see comments]. J Infect Dis 1994;169:1103-7
   PubMed Web of Science ®Google Scholar
• Jaruratanasirikul S, Sriwiriyajan S. Pharmacokinetic study of the interaction between itraconazole and nevirapine. Eur J Clin Pharmacol 2007;63:451-6
   PubMed Web of Science ®Google Scholar
• Kaul S, Ji P, Dudley J, Pharmacokinetic interaction between efavirenz and diltiazem or itraconazole after multiple-dose administration in adult healthy subjects [abstract 561]. 14th Conference on Retroviruses and Opportunistic Infections Los Angeles CA; 25 – 28 February 2007
   Google Scholar
• Koo HL, Hamill RJ, Andrade RA. Drug-drug interaction between itraconazole and efavirenz in a patient with AIDS and disseminated histoplasmosis. Clin Infect Dis 2007;45:e77-9
   PubMed Web of Science ®Google Scholar
• Andrade RA, Evans RT, Hamill RJ, Clinical evidence of interaction between itraconazole and nonnucleoside reverse transcriptase inhibitors in HIV-infected patients with disseminated Histoplasmosis. Ann Pharmacother 2009;43:908-13
   PubMed Web of Science ®Google Scholar
• MacKenzie-Wood AR, Whitfeld MJ, Ray JE. Itraconazole and HIV protease inhibitors: an important interaction [letter]. Med J Aust 1999;170:46-7
   PubMed Web of Science ®Google Scholar
• Crommentuyn KM, Mulder JW, Sparidans RW, Drug-drug interaction between itraconazole and the antiretroviral drug lopinavir/ritonavir in an HIV-1-infected patient with disseminated histoplasmosis. Clin Infect Dis 2004;38:e73-5
   PubMed Web of Science ®Google Scholar
• Hills-Nieminen C, Hughes C, Shafran S, Houston S. Drug-drug interaction between itraconazole and the protease inhibitor lopinavir/ritonavir. Ann Pharmacother 2009;43:2117-20
   PubMed Web of Science ®Google Scholar
• Schering-Plough Canada, Inc. Posanol (posaconazole) Package insert. Kirkland, QC; June 2008
   Google Scholar
• Schering-Plough. Noxafil (posaconazole) Package insert. Kenilworth, NJ; February 2009
   Google Scholar
• Rachwalski EJ, Wieczorkiewicz JT, Scheetz MH. Posaconazole: an oral triazole with an extended spectrum of activity. Ann Pharmacother 2008;42:1429-38
   PubMed Web of Science ®Google Scholar
• Ghosal A, Hapangama N, Yuan Y, Identification of human UDP-glucuronsyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil). Drug Metab Dispos 2004;32:267-71
   PubMed Web of Science ®Google Scholar
• Wexler D, Courtney R, Banfiled C, Effect of posaconazole on cytochrome P450 enzymes: a randomized open-label, two-way crossover study. Eur J Pharm Sci 2004;21(5):645-53
   PubMed Web of Science ®Google Scholar
• Krishna G, Moton A, Ma L, Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers. Clin Ther 2009;31:286-98
   PubMed Web of Science ®Google Scholar
• Krishna G, Moton A, Ma L, Effects of oral posaconazole on the pharmacokinetics of atazanavir alone and with ritonavir or with efavirenz in healthy adult volunteers. J Acquir Immune Defic Syndr 2009;51:437-44
   PubMed Web of Science ®Google Scholar
• Bruggemann RJM, van Luin M, van den Dungen MW, Bidirectional pharmacokinetic interaction between posaconazole and fosamprenavir. [abstract N-104]. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA; 16 – 19 February 2010
   Google Scholar
• Pasqualotto AC, Denning DW. New and emerging treatments for fungal infections. J Antimicrob Chemother 2008;61(Suppl 1):i19-30
   PubMedGoogle Scholar
• Yan J, Marino MR, Smith RA, The effect of ravuconazole on the pharmacokinetics of nelfinavir in healthy male volunteers. J Clin Pharmacol 2006;46:193-200
   PubMed Web of Science ®Google Scholar
• Pfizer Canada, Inc. VFEND* (voriconazole) Package insert. Kirkland, QC; October 2005
   Google Scholar
• Gerzenshtein L, Patel SM, Scarsi KK, Breakthrough Candida infections in patients receiving voriconazole. Ann Pharmacother 2005;39:1342-5
   PubMed Web of Science ®Google Scholar
• Liu P, Foster G, LaBadie RR, Pharmacokinetic interaction between voriconazole and efavirenz at steady-state in healthy male subjects. J Clin Pharmacol 2008;48:73-82
   PubMed Web of Science ®Google Scholar
• Damle B, LaBodie R, Crownover P, Glue P. Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteers. Br J Clin Pharmacol 2008;65:523-30
   PubMed Web of Science ®Google Scholar
• Carbonara S, Regazzi M, Ciraci E, Long-term efficacy and safety of TDM-assisted combination of voriconazole plus efavirenz in and AIDS patient with crytococcosis and liver cirrhosis. Ann Pharmacother 2009;43:978-84
   PubMed Web of Science ®Google Scholar
• Purkins L, Wood N, Kleinermans D, Love ER. No clinically significant pharmacokinetic interactions between voriconazole and indinavir in healthy volunteers. Br J Clin Pharmacol 2003;56:62-8
   PubMed Web of Science ®Google Scholar
• Theuretzbacher U, Ihle F, Derendorg H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 2006;45:649-63
   PubMed Web of Science ®Google Scholar
• Mikus G, Schowel V, Drzewinska M, Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. Clin Pharmacol Ther 2006;80:126-35
   PubMed Web of Science ®Google Scholar
• Liu P, Foster G, Gandelman K, Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects. Antimicrob Agents Chemother 2007;51:3617-26
   PubMed Web of Science ®Google Scholar
• Pfizer, Inc. VFEND (voriconazole) Package Insert. New York, NY; May 2008
   Google Scholar
• Scherpbier HJ, Hilhorst MI, Kuijpers TW. Liver failure in a child receiving highly active antiretroviral therapy and voriconazole. Clin Infect Dis 2003;37:828-30
   PubMed Web of Science ®Google Scholar
• Sucher AAJ, Chahin EB, Balcer HE. Echinocandins:the newest class of antifungals. Ann Pharmacother 2009;43: published online 1 September 2009
   Google Scholar
• McCormack PL, Perry CM. Caspofungin: a review of its use in the treatment of fungal infections. Drugs 2005;65:2049-68
   PubMed Web of Science ®Google Scholar
• Cross SA, Scott LJ. Micafungin: a review of its use in adults for the treatment of invasive and oesophageal candidiasis, and as prophylaxis against Candida infections. Drugs 2008;68:2225-55
   PubMed Web of Science ®Google Scholar
• Murdoch D, Plosker GL. Anidulafungin. Drugs 2004;64:2249-58
   PubMed Web of Science ®Google Scholar
• Merck Frosst Canada Ltd. Candidas (caspofungin) Product Monograph. Kirkland, QC; rev 2 April 2009
   Google Scholar
• Stone JA, Li S, Winchell G, Population pharmacokinetics of caspofungin in candidiasis patients [abstract no. A-1571]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, 14 – 17 September 2003
   Google Scholar
• Stone JA, Migoya EM, Hickey L, Potential for interactions between caspofungin and nelfinavir or rifampin. Antimicrob Agents Chemother 2004;48:4306-14
   PubMed Web of Science ®Google Scholar
• Lipp HP. Antifungal agents - clinical pharmacokinetics and drug interactions. Mycoses 2008;51(Suppl 1):7-18
   PubMedGoogle Scholar
• Jarvis B, Figgitt DP, Scott LJ. Micafungin. Drugs 2004;64:969-82
   PubMed Web of Science ®Google Scholar
• deWet N, Llamos-Cuentas A, Suleiman J, A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 2004;39:842-9
   PubMed Web of Science ®Google Scholar
• Undre N, Stevenson P, Amakye D. Rifampicin and ritonavir do not affect the pharmacokinetics of micafungin (FK463), an echinocandin antifungal. Presented at the 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague, Czech Republic; 1 – 4 May 2004
   Google Scholar
• Dowell JA, Knebel W, Ludden T, Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J Clin Pharmacol 2004;44:590-8
   PubMed Web of Science ®Google Scholar
• Vermes A, Guchelaar HJ, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother 2000;46:171-9
   PubMed Web of Science ®Google Scholar
• Novartis Pharmaceuticals Canada, Inc. Lamisil (terbinafine) Package Insert. Dorval, QC; January 2008
   Google Scholar
• Koks CH, van Heeswijk RP, Veldkamp AI, Itraconazole as an alternative for ritonavir liquid formulation when combined with saquinavir. AIDS 2000;14:89-90
   PubMed Web of Science ®Google Scholar